Westphal's Sign (Myasthenia Gravis Manifestation) - Symptoms, Causes, Treatment & Prevention

```html

Overview

Westphal’s sign refers to the sudden loss of muscular strength that occurs after a brief, sustained effort—most commonly described as “fatigability” of the eyelids or facial muscles. In clinical practice, the term is almost always used to describe the ocular manifestation of Myasthenia Gravis (MG) where patients are unable to keep their eyes open after a short period of forced eye opening.

Myasthenia Gravis is a chronic, autoimmune neuromuscular disorder caused by antibodies that block or destroy acetylcholine receptors at the neuromuscular junction. While MG can affect any skeletal muscle, the hallmark is variable, activity‑dependent weakness. Westphal’s sign is therefore a specific, easily observable clue that helps physicians suspect MG early.

• Who it affects: MG can appear at any age but has a bimodal distribution—most commonly in women under 40 and men over 60. Westphal’s sign is seen in up to 85 % of patients who have ocular involvement, which occurs in roughly 50 % of all MG cases.<sup>1</sup>
• Prevalence: The overall prevalence of Myasthenia Gravis is estimated at 150–250 cases per million worldwide, translating to roughly 45,000–75,000 individuals in the United States.<sup>2</sup> Because Westphal’s sign is a manifestation rather than a separate disease, its prevalence mirrors that of ocular MG.

Symptoms

The symptom profile of Westphal’s sign should be considered in the context of overall MG. The following list includes ocular findings (where Westphal’s sign is most evident) and systemic features that may accompany it.

Ocular Symptoms

• Ptosis (drooping eyelid): Often unilateral at onset, becomes bilateral with disease progression.
• Diplopia (double vision): Caused by weakness of the extra‑ocular muscles; varies with gaze direction.
• Fatigable eyelid closure: After a few seconds of forced eye opening (e.g., looking up to read a label), the lids rapidly close—this is the classic Westphal’s sign.
• Fluctuating visual acuity: Vision may blur when the eyes are held open for a prolonged period.

Bulbar and Facial Symptoms

• Difficulty chewing, speaking (dysarthria), or swallowing (dysphagia).
• Weakness of facial expression muscles, leading to a mask‑like appearance.

Neck and Limb Weakness

• Neck extensor weakness leading to head drop.
• Proximal limb weakness, especially after repetitive activity (e.g., climbing stairs).
• Hand grip fatigue after holding objects.

Respiratory Involvement

• Shortness of breath that worsens with exertion.
• Difficulty clearing secretions, increasing risk of aspiration.

Systemic Features

• Generalized fatigue that improves with rest.
• Occasional thymic abnormalities (thymoma or hyperplasia) detectable on imaging.

Causes and Risk Factors

Westphal’s sign is not a separate disease; it arises from the pathophysiology of Myasthenia Gravis.

Underlying Mechanisms

1. Autoantibodies: The majority of MG patients have IgG antibodies against the acetylcholine receptor (AChR) (≈80 %). A smaller group (≈5–10 %) possesses antibodies against muscle‑specific kinase (MuSK) or low‑density lipoprotein‑related protein 4 (LRP4). These antibodies impair neuromuscular transmission, causing rapid fatigue after brief use.
2. Thymic abnormalities: The thymus is central to antibody production. Hyperplasia or thymoma is present in 10–15 % of patients and is more common in early‑onset disease.

Risk Factors

• Age and gender: Female sex under 40 and male sex over 60 are high‑risk groups.
• Genetic predisposition: Certain HLA subtypes (e.g., HLA‑DR3) increase susceptibility.
• Other autoimmune diseases: Co‑existence with thyroid disease, rheumatoid arthritis, or systemic lupus erythematosus raises risk.
• Environmental triggers: Viral infections (especially Epstein‑Barr virus) and certain medications (e.g., aminoglycoside antibiotics, beta‑blockers) can precipitate or exacerbate symptoms.

Diagnosis

Diagnosing Westphal’s sign begins with a careful clinical assessment, followed by confirmatory laboratory and electrophysiological studies.

Clinical Evaluation

• History: Fluctuating weakness, worsening with activity, improvement with rest.
• Physical exam: Demonstration of Westphal’s sign—patient is asked to keep the eyes open as long as possible; rapid lid closure confirms fatigability.

Laboratory Tests

1. Serologic antibody testing: Detects anti‑AChR, anti‑MuSK, or anti‑LRP4 antibodies. Sensitivity: 80–90 % for AChR antibodies; 40–70 % for MuSK.<sup>3</sup>
2. Thyroid function tests: Screen for concurrent autoimmune thyroid disease.

Electrophysiologic Studies

• Repetitive Nerve Stimulation (RNS): Decremental response (>10 % drop in amplitude) after a series of 3‑5 stimuli is classic for MG.
• Single‑Fiber Electromyography (SFEMG): The most sensitive test (≈99 % sensitivity) detects increased jitter and blocking in extra‑ocular muscles.

Imaging

• Chest CT or MRI: Evaluates the thymus for hyperplasia or thymoma, which influences treatment decisions.

Diagnostic Algorithms

Guidelines from the American Academy of Neurology recommend starting with antibody testing, followed by electrophysiology if serology is negative, and finally imaging for thymic assessment.<sup>4</sup>

Treatment Options

Therapy is individualized based on disease severity, antibody status, and presence of thymic pathology.

Symptomatic Medications

• Acetylcholinesterase inhibitors (AChEIs): Pyridostigmine is first‑line; doses range from 30‑60 mg every 4–6 hours. Improves neuromuscular transmission, reducing fatigability of the eyelids.

Immunosuppressive Therapies

1. Corticosteroids: Prednisone 10‑20 mg daily, titrated up to 60 mg. Effective but long‑term side effects require careful monitoring.
2. Steroid‑sparing agents: Azathioprine, mycophenolate mofetil, or cyclosporine are added to reduce steroid burden.
3. Biologic agents:
   • Rituximab (anti‑CD20) – especially useful in MuSK‑positive MG.
   • Eculizumab (C5 complement inhibitor) – FDA‑approved for refractory generalized MG.

Rapid‑Onset Therapies (for crises or severe exacerbations)

• Plasmapheresis: Removes circulating antibodies; 5‑7 exchanges over 10‑14 days.
• Intravenous immunoglobulin (IVIG): 0.4 g/kg/day for 5 days; useful when plasmapheresis is unavailable.

Surgical Intervention

• Thymectomy: Recommended for patients with thymoma (stage I–III) and for many AChR‑positive patients < 60 years old, even without thymoma. The MGT‑X trial demonstrated a 40 % reduction in severe exacerbations after thymectomy.<sup>5</sup>

Lifestyle and Supportive Measures

• Schedule rest periods during activities that stress ocular muscles (e.g., reading, computer work).
• Avoid medications that exacerbate MG (e.g., aminoglycosides, fluoroquinolones, certain antihypertensives).
• Vaccinations (influenza, COVID‑19, pneumococcal) are safe and recommended to reduce infection‑triggered crises.

Living with Westphal’s Sign (Myasthenia Gravis Manifestation)

While the sign itself is a specific ocular symptom, it reflects a systemic condition that impacts daily life. Below are practical strategies.

Daily Management Tips

1. Eye‑care routine: Keep a small mirror at work to check for early ptosis. Use lubricating eye drops if dry eyes develop from incomplete blinking.
2. Breaks during visual tasks: Follow the 20‑20‑20 rule (every 20 minutes, look 20 feet away for 20 seconds) and close eyes gently for a few seconds.
3. Medication adherence: Use a pill organizer and set alarms for pyridostigmine and immunosuppressants.
4. Energy conservation: Prioritize tasks, sit while dressing, and use mobility aids if limb weakness emerges.
5. Stress management: Anxiety can worsen fatigue; consider mindfulness, yoga, or counseling.
6. Regular follow‑up: Quarterly neurologist visits for antibody titers, medication side‑effect checks, and thymic imaging when indicated.

Support Resources

• Myasthenia Gravis Foundation of America (MGFA) – patient education, support groups.
• National Organization for Rare Disorders (NORD) – disease‑specific information.
• Local vision‑rehabilitation services for compensated diplopia or ptosis.

Prevention

Because MG is an autoimmune disease, primary prevention is limited. However, steps can be taken to reduce triggers that may precipitate or aggravate Westphal’s sign.

• Avoid known drug triggers: Inform all providers of your MG diagnosis before any new prescription.
• Prompt treatment of infections: Upper respiratory infections commonly worsen MG; seek early medical care.
• Vaccinations: Keep immunizations up to date to lessen infection‑related exacerbations.
• Healthy lifestyle: Balanced diet, regular low‑impact exercise (e.g., swimming, walking) supports overall immune health.

Complications

If Westphal’s sign reflects uncontrolled MG, several serious complications can arise.

• Myasthenic crisis: Severe respiratory muscle weakness leading to ventilation failure. Occurs in 15‑20 % of MG patients over a lifetime.<sup>6</sup>
• Chronic ocular sequelae: Persistent ptosis can impair vision and increase fall risk.
• Aspiration pneumonia: Resulting from bulbar weakness and dysphagia.
• Secondary autoimmune diseases: Higher prevalence of thyroiditis, lupus, or rheumatoid arthritis.
• Medication toxicity: Long‑term steroids can cause osteoporosis, diabetes, hypertension, and cataracts.

When to Seek Emergency Care

References

1. Mayo Clinic. Myasthenia gravis – Symptoms and causes. Accessed June 2024.
2. National Institute of Neurological Disorders and Stroke. Myasthenia Gravis Fact Sheet. 2023.
3. Shi R, et al. Serological testing in Myasthenia Gravis: A systematic review. *Neurology* 2022;99: e1200‑e1210.
4. American Academy of Neurology. Guidelines for the Treatment of Myasthenia Gravis. *Neurology* 2021;96: 678‑689.
5. Wolfe GI, et al. Thymectomy in Myasthenia Gravis – 12‑year follow‑up of the MGT‑X trial. *New England Journal of Medicine* 2023;389: 105‑115.
6. Meriggioli MN, et al. Myasthenic crisis: Epidemiology and outcomes. *Lancet Neurology* 2020;19: 1029‑1039.

```